Clostridium difficile infection: a new threat on our doorstep

Rhonda L Stuart and Caroline Marshall
Med J Aust 2011; 194 (7): . || doi: 10.5694/j.1326-5377.2011.tb02998.x
Published online: 4 April 2011

What can we do to prevent this from becoming the most common health care-associated infection in Australia?

Clostridium difficile, a gram-positive, anaerobic, spore-forming, toxigenic bacterium, is the most common infectious cause of nosocomial diarrhoea. The severity of infection varies from mild diarrhoea to pseudomembranous colitis, toxic megacolon and death.1 In the United States, C. difficile now rivals methicillin-resistant Staphylococcus aureus (MRSA) as the most common health care-associated infection, accounting for US$3.2 billion in excess costs annually.1,2

  • 1 Department of Infectious Diseases, Monash Medical Centre, Southern Health, Melbourne, VIC.
  • 2 Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC.
  • 3 Department of Medicine, University of Melbourne, Melbourne, VIC.

  • 1. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis 2006; 12: 409-415.
  • 2. Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1: S81-S92.
  • 3. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145: 758-764.
  • 4. Bauer M, Goorhuis A, Koster T, et al. Community-onset Clostridium difficile-associated diarrhoea not associated with antibiotic usage — two case reports with review of the changing epidemiology of Clostridium difficile-associated diarrhoea. Neth J Med 2008; 66: 207-211.
  • 5. Severe Clostridium difficile-associated disease in populations previously at low risk — four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54: 1201-1205.
  • 6. Riley TV, Thean S, Hool G, Golledge CL. First Australian isolation of epidemic Clostridium difficile PCR ribotype 027. Med J Aust 2009; 190: 706-708. <MJA full text>
  • 7. Richards M, Knox J, Elliot B, et al. Severe infection with Clostridium difficile PCR ribotype 027 acquired in Melbourne, Australia. Med J Aust 2011; 194: 369-371. <MJA full text>
  • 8. McGregor A, Riley TV, Van Gessel H. Clostridium difficile associated disease. In: Cruikshank M, Ferguson J, editors. Reducing harm to patients from healthcare associated infection: the role of surveillance. Sydney: Australian Commission on Safety and Quality in Healthcare, 2008: 171-187.
  • 9. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-455.
  • 10. Cheng AC, Ferguson JK, Richards MJ, et al. Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med J Aust 2011; 194: 353-358. <MJA full text>
  • 11. Stuart RL, Marshall C, McLaws ML, et al. ASID/AICA position statement: infection control guidelines for patients with Clostridium difficile infection in health care settings. Healthcare Infect 2011. In press.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.